MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma

This contractor does not cover any current molecular biomarker tests intended to risk-stratify individuals with cutaneous squamous cell carcinoma (cSCC). Claims for molecular biomarker testing for cSCC risk stratification should be treated as non-covered services under this policy.

"All current molecular biomarker tests used to risk-stratify individuals with cutaneous squamous cell carcinoma (cSCC) are not covered by this contractor."

Sign up to see full coverage criteria, indications, and limitations.